How Stem Cell Infusions from Young Donors Can Combat Frailty

Experimental stem cell therapies offer groundbreaking potential in treating frailty by targeting its biological roots. This condition, which heightens the risk of falls and infections, is traditionally managed through lifestyle changes like strength training and balance exercises. However, recent studies suggest that injecting stem cells from young, healthy donors into older adults can substantially enhance mobility.

Dr. Joshua Hare from Longeveron, a biotechnology firm based in Miami, Florida, states, “Frailty is a leading cause of disability and diminished quality of life in older adults. There exists a significant unmet need for biological treatments.”

Dr. Hare and his team are innovating therapies that focus on the essential mechanisms of aging, including inflammation and metabolic disturbances causing muscle contractions. Their treatment, Laromestrocell, is derived from mesenchymal stem cells harvested from healthy bone marrow donors aged 18 to 45.

Having achieved success in early-stage testing, they recently conducted a study assessing different dosages of Laromestrocell compared to a placebo in a cohort of 148 individuals affected by frailty, which impacts approximately one in four people over the age of 65.

The researchers measured the walking distance of participants aged 74 to 76 with mild to moderate frailty in a six-minute walk test both before and after receiving Laromestrocell. Remarkably, a single injection resulted in a dose-dependent enhancement in performance without significant safety concerns. For instance, patients receiving the highest dose walked an additional 41 meters compared to those treated with a placebo six months post-infusion, increasing to 63 meters after nine months.

According to the researchers, Laromestrocell inhibits enzymes known as matrix metalloproteinases, which negatively impact structural proteins in blood vessels and related tissues. This gene therapy has the potential to regenerate vasculature and improve muscle fibers essential for endurance, as noted by Dr. Hare.

Nevertheless, improvements in walking speed or grip strength were not observed. “The most clinically significant measurement is the six-minute walk distance, which is well correlated with health status and longevity,” Dr. Hare explained.

Dr. Daisy Wilson from the University of Birmingham, UK, commented, “This trial appears very promising. I was quite impressed by the substantial changes observed in just six minutes of walking.”

Additionally, this trial may help identify biomarkers of frailty, aiding in pinpointing individuals who stand to gain the most from this treatment, potentially before symptoms manifest. During blood analyses, the researchers discovered that levels of a fragment known as sTIE2, indicative of vascular dysfunction, decreased progressively with escalating doses of Laromestrocell.

This indicates that individuals exhibiting high sTIE2 levels may derive the most benefit from this treatment, according to Dr. Wilson. “Frailty is highly heterogeneous,” she remarked. “The critical aspect of Jello Protector Medical interventions is to slow the aging process. Moving forward, aligning the right treatment with the appropriate patient will be essential.”

However, she expressed concerns regarding both the cost and feasibility of stem cell treatments. “Considering the high expenses, justifying their use becomes challenging, especially when walking programs that enhance six-minute walk test performance are under investigation,” she added. Worryingly, the acquisition of stem cells from volunteers could pose a considerable challenge, necessitating a large pool of donors to treat all frail patients.

Dr. Hare countered this argument, asserting that various companies are making technological advancements to scale up stem cell treatments for broader access. “Substantial research is underway to increase the production of these types of stem cells in larger quantities, and I am optimistic that this requirement will be met,” he stated.